Quarterly Revenue: INR701 crore, a 16% increase year-on-year and quarter-on-quarter. Annual Revenue: INR2,349 crore, reflecting a growth of 14% from FY24. Quarterly Operating EBITDA: INR179 crore, a growth of 62% year-on-year. Annual Operating EBITDA: INR534 crore, up by 34% from FY24. Quarterly EBITDA Margin: 25.5%, compared to 18.3% in Q4 FY24. Annual EBITDA Margin: 22.7%, up from 19.3% in FY24. Quarterly Operating PBT: INR115 crore, a 72% increase from Q4 FY24. Annual Operating PBT: INR336 crore, an increase of 48% from FY24. Quarterly Profit After Tax: INR95 crore, a 35% increase from Q4 FY24. Annual Profit After Tax: INR289 crore, compared to INR271 crore in FY24. Net Debt to Equity Ratio: 0.37 as of March 31, 2025. Operating Cash Flow: INR571 crore for the past year.

Warning! GuruFocus has detected 9 Warning Signs with BOM:532504.

Release Date: May 09, 2025

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

Navin Fluorine International Ltd (BOM:532504) reported its highest ever revenue of INR2,349 crore for FY25, with quarterly revenues reaching INR701 crore. The company achieved an impressive EBITDA margin of 25.5% in Q4 FY25, up from 18.3% in the same quarter last year. A strategic agreement with Chemours was announced to produce Opteon, a two-phase immersion cooling fluid, marking a significant foray into the advanced materials segment. The R32 project was commercialized in March 2025 and is operating at optimal capacity, with strong demand and pricing traction. The company has a robust order book visibility in its CDMO business and a strong pipeline in the Specialty Chemical business, indicating future growth potential.

Negative Points

Despite strong performance, the company faces pricing pressures in the Specialty Chemical segment due to raw material cost increases. The company's guidance for EBITDA margins remains cautious at 23% to 26%, reflecting uncertainties in the global market environment. The initial capacity for the Chemours partnership is limited, and scalability will depend on market adoption and further discussions. There is a lack of clarity on the exact financial impact and margin profile of the Opteon project due to confidentiality agreements. The company has not yet announced any specific CapEx for the Buss ChemTech AG partnership, which could delay potential benefits from this collaboration.

Q & A Highlights

Q: Can you provide more details on the strategic agreement with Chemours and its potential impact on Navin Fluorine? A: Anish Ganatra, CFO, explained that the agreement with Chemours is a significant step into the advanced materials sector, focusing on manufacturing a new two-phase immersion cooling fluid. This partnership is expected to enhance Navin Fluorine's capabilities in high-end technology absorption and commercialization. The initial capacity is set to help Chemours accelerate market adoption, with potential for scaling up as demand increases.

Story Continues

Q: What is the outlook for the CDMO business, and how does it align with Navin Fluorine's strategic goals? A: Anish Ganatra, CFO, stated that the CDMO business is progressing well, with a focus on balancing early and late-stage molecules to reduce revenue lumpiness. The company aims to achieve a $100 million milestone by FY27, driven by existing contracts, new MSAs, and base business growth. The strategy includes leveraging innovative molecules and expanding partnerships.

Q: How is Navin Fluorine addressing the demand and pricing dynamics in the R32 market? A: Anish Ganatra, CFO, noted that the R32 market remains strong, with robust demand and strategic discussions with global partners. The company is cautious about providing specific pricing guidance but remains optimistic about capacity utilization and market opportunities.

Q: Can you elaborate on the partnership with Buss ChemTech AG and its implications for Navin Fluorine? A: Nitin Kulkarni, Managing Director, explained that the partnership with Buss ChemTech AG focuses on producing high-purity HF for solar and electronic applications. This aligns with Navin Fluorine's strategy to enhance value from HF production and cater to global markets, including Indias growing solar capacity.

Q: What are the financial expectations for FY26, particularly regarding margins and CapEx? A: Anish Ganatra, CFO, indicated that the company aims to maintain an EBITDA margin of 25%, despite global uncertainties. The CapEx plan includes ongoing projects like the AHF plant and cGMP-4, with a budget capability of INR500-600 crore, supported by a strong balance sheet.

Q: How is Navin Fluorine's R&D contributing to new product development and market expansion? A: Anish Ganatra, CFO, highlighted that Navin Fluorine is strengthening its R&D capabilities in Surat and Dewas to support both product and service plays. The focus is on developing high-value products and leveraging manufacturing excellence for strategic partnerships and market expansion.

Q: What is the status of the fluoro-specialty project, and how does it impact future growth? A: Anish Ganatra, CFO, reported that the fluoro-specialty project is progressing through a three-stage process, with expectations to reach 50-55% utilization by the end of FY26. This project is crucial for meeting demand and supporting revenue growth.

Q: How does Navin Fluorine plan to manage inventory and working capital efficiently? A: Anish Ganatra, CFO, stated that the company has reduced inventory days to 90, aligning procurement with order books. This disciplined approach is sustainable and supports efficient working capital management.

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

This article first appeared on GuruFocus.

View Comments